1-3 of 3
Jerry P. Radich
Close
Sort by
Journal Articles

Second Treatment Free Remission after Combination Therapy with Ruxolitinib Plus Tyrosine Kinase Inhibitors in Chronic Phase Chronic Myeloid Leukemia (CML)

Kendra Sweet, Ehab L. Atallah, Jerry P. Radich, Mei-Jie Zhang, Eva Sahakian, Melanie Mediavilla-Varela, Alexis Vistocky, Michael C. Heinrich, James E. Thompson, Michael J. Mauro, Kathryn E Flynn, Arielle Baim, Javier Pinilla Ibarz
Journal: Blood
Blood (2021) 138 (Supplement 1): 2555.
https://doi.org/10.1182/blood-2021-147954
Published: 2021
Journal Articles

Reduced-Intensity Therapy with Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) Yields Durable Remissions in Adults with Newly-Diagnosed Acute Lymphoblastic Leukemia/Lymphoma (ALL): Final Results of a Phase II Trial

Ryan D. Cassaday, Kelsey-Leigh A. Garcia, Olga Sala-Torra, Philip A. Stevenson, Christen H. Martino, Yajuan J. Liu, Min Fang, Mary-Elizabeth M. Percival, Anna B. Halpern, Pamela S. Becker, Vivian G. Oehler, Andrei R Shustov, Jason P. Cooper, Johnnie J. Orozco, Paul C. Hendrie, Roland B. Walter, Jerry P. Radich, Lorinda A. Soma, Elihu H. Estey
Journal: Blood
Blood (2021) 138 (Supplement 1): 4397.
https://doi.org/10.1182/blood-2021-145648
Published: 2021
Journal Articles

Minimal Toxicity Seen When Pembrolizumab Is Added to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease: Early Results from an Ongoing Phase II Trial (ECOG-ACRIN EA9171)

Amer M. Zeidan, Kevin Roopcharan, Jerry P. Radich, Jan Philipp Bewersdorf, Vijaya R. Bhatt, Elad Sharon, Richard F. Little, Steven D. Gore, Anne Caldwell, Selina M. Luger, Mark R. Litzow
Journal: Blood
Blood (2021) 138 (Supplement 1): 3613.
https://doi.org/10.1182/blood-2021-145015
Published: 2021